Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART.
Lombardi F, Belmonti S, Rapone L, Borghetti A, Ciccullo A, Gagliardini R, Baldin G, Montagnani F, Moschese D, Emiliozzi A, Rossetti B, De Luca A, Di Giambenedetto S. Lombardi F, et al. Among authors: baldin g. J Clin Virol. 2018 Jun;103:57-62. doi: 10.1016/j.jcv.2018.03.013. Epub 2018 Apr 2. J Clin Virol. 2018. PMID: 29656086
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.
Belmonti S, Lombardi F, Quiros-Roldan E, Latini A, Castagna A, Borghetti A, Baldin G, Ciccullo A, Cauda R, De Luca A, Di Giambenedetto S; ATLAS-M Study Group. Belmonti S, et al. Among authors: baldin g. J Antimicrob Chemother. 2018 Jul 1;73(7):1949-1954. doi: 10.1093/jac/dky125. J Antimicrob Chemother. 2018. PMID: 29788156 Clinical Trial.
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice.
Ciccullo A, D'Avino A, Lassandro AP, Baldin G, Borghetti A, Dusina A, Emiliozzi A, Gagliardini R, Moschese D, Belmonti S, Lombardi F, Di Giambenedetto S. Ciccullo A, et al. Among authors: baldin g. Infez Med. 2018 Dec 1;26(4):336-340. Infez Med. 2018. PMID: 30555137 Free article.
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Borghetti A, Lombardi F, Gagliardini R, Baldin G, Ciccullo A, Moschese D, Emiliozzi A, Belmonti S, Lamonica S, Montagnani F, Visconti E, De Luca A, Di Giambenedetto S. Borghetti A, et al. Among authors: baldin g. BMC Infect Dis. 2019 Jan 17;19(1):59. doi: 10.1186/s12879-018-3666-8. BMC Infect Dis. 2019. PMID: 30654739 Free PMC article.
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study.
Rossetti B, Baldin G, Sterrantino G, Rusconi S, De Vito A, Giacometti A, Gagliardini R, Colafigli M, Capetti A, d'Ettorre G, Celani L, Lagi F, Ciccullo A, De Luca A, Di Giambenedetto S, Madeddu G. Rossetti B, et al. Among authors: baldin g. Antiviral Res. 2019 Sep;169:104552. doi: 10.1016/j.antiviral.2019.104552. Epub 2019 Jul 5. Antiviral Res. 2019. PMID: 31283942 Free article.
83 results